For THIS Weeks @oncoalert 🚨 @vjoncology JOURNAL CLUB: A pleasure to present Petros Grivas of Fred Hutch Cancer Center discussing his paper on Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of

17° Corso in Genetica Oncologica. 26-27 SETT - LAC Lugano. INFO-ISCRIZIONI: swisscancerinstitute.ch/en/latest-news…

With the increasing use of CDK4/6 inhibitors in the early setting of HR+ BC treatment, a growing proportion of patients (≈10%) will develop #resistance during or shortly after adjuvant endocrine therapy. In ESMO Open, we tried to address what we know and what we are still

Ente Ospedaliero Cantonale Don’t miss the 17th Course in Genetic Counseling in Oncology in Lugano. We’re honored by Swiss Experts, Dr Judy Garber judy garber , Dr Huma Rana Huma Rana, MD, MPH, Matthew Yurgelun Matt Yurgelun, MD and Dr Matteo Lambertini @Matteolambe. Sign up as soon as possible

Looking forward and thanks for the kind invitation 💪 Università di Genova OncoAlert

The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week Sept 5-11, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅ EGFR+ #NSCLC : Amivantamab–Lazertinib vs Osimertinib🫁 Amivantamab–lazertinib boosts 3-year OS to 60% vs 51% in

Evaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2)-negative metastatic #BreastCancer buff.ly/FKBThyQ This single-center, retrospective cohort study evaluated sequencing of antibody-drug conjugates

A Caserta l’evento “Dal bench alla pratica clinica: l’integrazione molecolare nei test in oncologia”. Un confronto prezioso tra discipline e professioni diverse: solo con un approccio multidisciplinare e integrato possiamo offrire diagnosi più precise e terapie personalizzate.

🔝🔝🔝Matteo Lambertini, MD PhD Asociación Argentina de Oncología Clínica (AAOC)

The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week Sept 12-18, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: 🔹 PRIME Diagnostic Trial (JAMA): Biparametric MRI is noninferior to multiparametric MRI for #ProstateCancer 🔹

🚨 New Oncology Journal Club OncoAlert & VJ Oncology proudly present Dr. Rinath Jeselsohn (Dana-Farber) as she presents key findings from the PACE trial, exploring ctDNA dynamics in patients with HR+/HER2- metastatic #BreastCancer Article Found Here 👉 esmoopen.com/article/S2059-…

Really grateful to my 🇦🇷 friends for the opportunity to contribute to the important Asociación Argentina de Oncología Clínica (AAOC) Congress and, as always, for the fantastic hospitality & friendship…looking forward to even more collaborations in the #BreastCancer field in the future! Università di Genova OncoAlert

NEWS FROM INDUSTRY 🚨 SOURCE: ROCHE #BreastCancer Roche announced positive phase III results from the evERA trial, showing that giredestrant plus everolimus significantly improved progression-free survival in patients with ER-positive, HER2-negative advanced breast cancer

COLLEAGUES AT #ESMO25 🇩🇪 WELCOME to the #OncoAlert5k 🚨 REGISTER👉 buff.ly/XKcB0W8 SATURDAY October 18, 2025 7AM departure (Arrive 6:45AM at latest) Meeting Point at the Brandenburg Gate RUNNING ROUTE VIA Map My Run APP (QR code ) REGISTRATION Necessary. Event Open

My Top 10 Breast Cancer Abstracts list at #ESMO25 👇

Here we are….today I turned 40….it’s a strange feeling but I can absolutely say that I’m proud and extremely grateful for everything I’ve had up to now…I truly want to thank all the people who have helped me find myself in such a privileged situation today…GRAZIE MILLE !!! ❤️

The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week Sept 19-25, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅evERA Update : Oral SERD giredestrant + everolimus improves PFS in ER+/HER2– advanced Breast #Cancer ✅FDA

📌Attualità in senologia “Gravidanza dopo tumore al seno in giovani donne con mutazione BRCA” 🧬Pregnancy after breast cancer in young BRCA carriers Matteo Lambertini, MD PhD 👏🏻👏🏻 OncoAlert #OncoAlertAF #AIS25 #breastcancer

#ESMOAmbassadors #bcsm Both DB-11 (neoadj T-DXd) and DB-05 (residual disease T-DXd) will be presented back-to-back at #ESMO25, Saturday October 18th 4:30pm in the presidential #1 session . This is the presidential session for #bcsm folks to attend! Put it on your 📅!

The U.S. FDA has approved imlunestrant, an oral estrogen receptor antagonist, for the treatment of adults with ER+, HER2–, ESR1-mutated advanced or metastatic #BreastCancer that has progressed after at least one line of endocrine therapy. buff.ly/weJEKUh The approval